Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.96 [0.81, 1.15] | | < 1 | | 0% | 5 studies (5/-) | 65.8 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.83 [0.65, 1.05] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | important | - |
PFS (extension) | 0.95 [0.77, 1.18] | | < 1 | | 0% | 1 study (1/-) | 68.1 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.90 [0.69, 1.16] | | < 1 | | 80% | 6 studies (6/-) | 79.4 % | some concern | not evaluable | moderate | important | - |
DCR | 1.85 [0.77, 4.45] | | > 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.22 [0.80, 1.86] | | > 1 | | 48% | 5 studies (5/-) | 82.3 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) (extension) | 0.77 [0.44, 1.36] | | > 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 1.18 [0.48, 2.89] | | < 1 | | 52% | 4 studies (4/-) | 35.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.67 [0.35, 1.31] | | < 1 | | 83% | 4 studies (4/-) | 87.8 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-5) | 1.40 [0.91, 2.15] | | < 1 | | 0% | 1 study (1/-) | 6.3 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.85 [0.36, 1.99] | | < 1 | | 0% | 4 studies (4/-) | 64.9 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 1.43 [0.38, 5.40] | | < 1 | | 60% | 3 studies (3/-) | 29.8 % | some concern | not evaluable | moderate | non important | - |
SAE (any grade) | 1.22 [0.61, 2.41] | | < 1 | | 68% | 3 studies (3/-) | 28.8 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 1.41 [0.35, 5.60] | | < 1 | | 78% | 2 studies (2/-) | 31.4 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.18 [0.01, 2.73] | | < 1 | | 89% | 2 studies (2/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.24 [0.07, 0.91] | | < 1 | | 93% | 3 studies (3/-) | 98.2 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.57 [0.16, 2.08] | | < 1 | | 0% | 4 studies (4/-) | 80.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 3.77 [0.17, 84.42] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.26 [0.05, 1.26] | | < 1 | | 0% | 1 study (1/-) | 95.2 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.09 [0.00, 1.67] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 9.63 [0.52, 177.85] | | < 1 | | 0% | 1 study (1/-) | 6.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.18 [0.05, 0.66] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
Dizziness TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
Epistaxis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.20 [0.06, 0.72] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 7.65 [0.40, 146.03] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.88 [0.17, 20.97] | | < 1 | | 0% | 1 study (1/-) | 30.5 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 2.84 [0.29, 27.62] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 1.37 [0.24, 7.75] | | < 1 | | 0% | 2 studies (2/-) | 36.0 % | some concern | not evaluable | moderate | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.93 [0.06, 15.08] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 0.93 [0.13, 6.72] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.09 [0.00, 1.67] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
hepatitis (Autoimmune) AE (grade 3-4) | 1.61 [0.14, 18.49] | | < 1 | | 0% | 2 studies (2/-) | 35.2 % | some concern | not evaluable | moderate | non important | - |
Abdominal pain AE (grade 3-4) | 0.81 [0.38, 1.73] | | < 1 | | 0% | 3 studies (3/-) | 71.1 % | some concern | not evaluable | moderate | non important | - |
Acute kidney injury AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
Alopecia AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.73 [0.22, 2.48] | | < 1 | | 44% | 3 studies (3/-) | 69.1 % | some concern | not evaluable | moderate | non important | - |
Arthralgia AE (grade 3-4) | 0.57 [0.08, 4.06] | | < 1 | | 0% | 3 studies (3/-) | 71.2 % | some concern | not evaluable | moderate | non important | - |
Asthenia AE (grade 3-4) | 1.06 [0.31, 3.69] | | < 1 | | 23% | 3 studies (3/-) | 46.2 % | some concern | not evaluable | moderate | non important | - |
Back pain AE (grade 3-4) | 2.02 [0.37, 11.03] | | < 1 | | 0% | 3 studies (3/-) | 20.9 % | some concern | not evaluable | moderate | non important | - |
Colitis AE (grade 3-4) | 1.79 [0.18, 17.83] | | < 1 | | 0% | 2 studies (2/-) | 31.1 % | some concern | not evaluable | moderate | non important | - |
Constipation AE (grade 3-4) | 0.90 [0.11, 7.78] | | < 1 | | 0% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
Cough AE (grade 3-4) | 0.72 [0.07, 6.94] | | < 1 | | 0% | 3 studies (3/-) | 61.2 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite AE (grade 3-4) | 0.23 [0.05, 0.99] | | < 1 | | 0% | 3 studies (3/-) | 97.6 % | some concern | not evaluable | moderate | non important | - |
Dermatitis acneiform AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea AE (grade 3-4) | 0.67 [0.20, 2.24] | | < 1 | | 66% | 3 studies (3/-) | 74.1 % | some concern | not evaluable | moderate | non important | - |
Dizziness AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dry skin AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dysgeusia AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
Dyspepsia AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dysphonia AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
Dyspnoea AE (grade 3-4) | 0.91 [0.08, 10.12] | | < 1 | | 0% | 2 studies (2/-) | 53.0 % | some concern | not evaluable | moderate | non important | - |
Epistaxis AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.48 [0.26, 0.90] | | < 1 | | 0% | 3 studies (3/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
Guillain-Barré syndrome AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
Headache AE (grade 3-4) | 0.90 [0.11, 7.78] | | < 1 | | 0% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
Hypertension AE (grade 3-4) | 0.33 [0.06, 1.92] | | < 1 | | 83% | 3 studies (3/-) | 89.0 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.25 [0.28, 5.70] | | < 1 | | 0% | 1 study (1/-) | 38.6 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 0.85 [0.23, 3.05] | | < 1 | | 0% | 3 studies (3/-) | 60.1 % | some concern | not evaluable | moderate | non important | - |
Infusion-related reaction AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
Intestinal perforation AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
Mucosal inflammation AE (grade 3-4) | 0.95 [0.13, 6.90] | | < 1 | | 0% | 3 studies (3/-) | 52.0 % | some concern | not evaluable | moderate | non important | - |
Myalgia AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
Nausea AE (grade 3-4) | 0.73 [0.23, 2.28] | | < 1 | | 0% | 3 studies (3/-) | 70.6 % | some concern | not evaluable | moderate | non important | - |
Neutropenia AE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.06 [0.01, 0.36] | | < 1 | | 0% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.36 [0.05, 2.55] | | < 1 | | 0% | 3 studies (3/-) | 84.7 % | some concern | not evaluable | moderate | non important | - |
Peripheral oedema AE (grade 3-4) | 0.70 [0.10, 4.74] | | < 1 | | 0% | 3 studies (3/-) | 64.4 % | some concern | not evaluable | moderate | non important | - |
Peripheral sensory neuropathy AE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 1.26 [0.11, 14.04] | | < 1 | | 0% | 2 studies (2/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
Pruritus AE (grade 3-4) | 0.56 [0.06, 4.80] | | < 1 | | 0% | 3 studies (3/-) | 70.2 % | some concern | not evaluable | moderate | non important | - |
Pyrexia AE (grade 3-4) | 2.72 [0.40, 18.53] | | < 1 | | 0% | 3 studies (3/-) | 15.5 % | some concern | not evaluable | moderate | non important | - |
Rash AE (grade 3-4) | 1.05 [0.32, 3.48] | | < 1 | | 0% | 3 studies (3/-) | 47.0 % | some concern | not evaluable | moderate | non important | - |